In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium
-
- Michael P Lorenzo
- Department of Pharmacy, Rhode Island Hospital, Providence, RI, USA
-
- James M Kidd
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA
-
- Stephen G Jenkins
- Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA
-
- David P Nicolau
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA
-
- Seth T Housman
- Western New England University College of Pharmacy and Health Sciences, Springfield, MA, USA
説明
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>To assess activity of the combination of ceftriaxone and ampicillin against clinical isolates of ampicillin-susceptible Enterococcus faecium.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Ampicillin-susceptible E. faecium (n = 29) and Enterococcus faecalis (n = 10) collected from locations in the USA and France were used for this analysis. Susceptibility testing was performed by gradient diffusion strip (GDS) and broth microdilution (BMD). Synergy with the combination of ceftriaxone and ampicillin was assessed in all isolates using GDS crossing and double disc diffusion methods. Selected isolates (nine E. faecium and three E. faecalis) were assessed for synergy in time–kill studies using ampicillin alone and in combination with ceftriaxone.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In isolates of E. faecium, the median (range) ampicillin MIC by BMD was 0.5 (0.25–4) mg/L and by GDS it was 2 (1–8) mg/L. In E. faecalis, the median (range) ampicillin MIC by BMD was 0.5 (0.5–1) mg/L and by GDS it was 2 (0.75–3) mg/L. A total of 24/29 (82.8%) isolates of E. faecium displayed synergy by GDS and 22/29 (75.9%) by double disc diffusion. Seven of 10 (70%) isolates of E. faecalis displayed synergy by GDS and 4/10 (40%) by double disc diffusion. Time–kill studies found synergy in 3/9 (33.3%) E. faecium and 3/3 (100%) E. faecalis.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In contrast to the demonstrated synergy in time–kill models of ceftriaxone and ampicillin for E. faecalis, this combination does not appear to provide uniform synergy in E. faecium. Antagonism was not observed. Clinical correlation is necessary and caution should be used when considering ampicillin and ceftriaxone for the treatment of infections caused by ampicillin-susceptible E. faecium.</jats:p></jats:sec>
収録刊行物
-
- Journal of Antimicrobial Chemotherapy
-
Journal of Antimicrobial Chemotherapy 74 (8), 2269-2273, 2019-05-03
Oxford University Press (OUP)